Skip to main content
Equibles

UBS Group AG

Position in GILD — Gilead Sciences, Inc.

CIK 1610520 ZURICH, V8
Back to GILD Full portfolio

Position in GILD

as of Jun 30, 2026 · filed Aug 13, 2026
Position Value
$568,946,162
+$21,191,960 QoQ
Shares Held
4,503,294
+14.6% QoQ
Ownership
0.363%
of shares outstanding
% of Portfolio
0.12%
of 13F equity value
Holder Rank
#36
of 2,275 holders
Holding Since
Mar 2020
26 quarters on record
Voting authority Sole 75% Shared 0% None 25%

Common Shares in GILD Over Time

Shares Held

Position Value (USD)

Derivatives in GILD

reported options exposure · as of Jun 30, 2026
CallValue
$16,801,703
CallShares
132,988
PutValue
$4,838,822
PutShares
38,300

Notional value of option positions as reported on Form 13F. Calls and puts are disclosed separately and do not net against the common-share stake above.

Position in Drug Manufacturers - General

Healthcare · as of Jun 30, 2026

UBS Group AG holds $17,056,271,930 across 20 Drug Manufacturers - General names. GILD ranks #7 (3.3% of the industry book) .

# Ticker Company Shares Value (USD) Open
1 LLY
ELI LILLY & Co
 3,865,931 $4,636,914,000
2 ABBV
AbbVie Inc.
 12,845,120 $3,232,345,993
3 JNJ
Johnson & Johnson
 11,036,891 $2,803,039,201
4 MRK
Merck & Co., Inc.
 13,744,783 $1,766,204,613
5 AMGN
Amgen Inc
 3,308,695 $1,198,144,628
6 AZN
Astrazeneca PLC
 5,297,462 $1,004,504,738
7 GILD
Gilead Sciences, Inc.
This page 		4,503,294 $568,946,162
8 BMY
Bristol Myers Squibb Co
 8,876,439 $511,460,413

All Filings in GILD

Export CSV
50 filing rows on record
Report Date Value (USD) Shares
2026-06-30 $4,838,822 38,300
2026-06-30 $568,946,162 4,503,294
2026-06-30 $16,801,703 132,988
2026-03-31 $10,522,435 75,500
2026-03-31 $547,754,202 3,930,216
2026-03-31 $19,287,135 138,388
2025-12-31 $41,522,942 338,300
2025-12-31 $586,657,799 4,779,679
2025-12-31 $29,468,401 240,088
2025-09-30 $571,393,035 5,147,685
2025-09-30 $41,436,300 373,300
2025-09-30 $34,741,668 312,988
2025-06-30 $40,755,812 367,600
2025-06-30 $505,658,333 4,560,822
2025-06-30 $31,951,403 288,188
2025-03-31 $60,555,181 540,430
2025-03-31 $518,368,171 4,626,222
2025-03-31 $63,117,765 563,300
2024-12-31 $451,099,976 4,883,620
2024-12-31 $94,494,510 1,023,000
2024-12-31 $59,143,402 640,288
2024-09-30 $58,520,320 698,000
2024-09-30 $346,923,459 4,137,923
2024-09-30 $42,782,545 510,288
2024-06-30 $308,521,669 4,496,745
2024-06-30 $28,012,639 408,288
2024-06-30 $36,479,937 531,700
2024-03-31 $308,669,200 4,213,914
2024-03-31 $25,725,400 351,200
2024-03-31 $45,451,625 620,500
2023-12-31 $47,949,819 591,900
2023-12-31 $105,240,091 1,299,100
2023-12-31 $288,096,668 3,556,310
2023-09-30 $94,956,474 1,267,100
2023-09-30 $232,682,179 3,104,913
2023-09-30 $46,440,318 619,700
2023-06-30 $42,334,551 549,300
2023-06-30 $258,722,677 3,356,983
2023-06-30 $81,486,111 1,057,300
2023-03-31 $173,222,938 2,087,778
2023-03-31 $63,530,129 765,700
2023-03-31 $115,286,815 1,389,500
2022-12-31 $164,775,768 1,919,345
2022-12-31 $61,365,580 714,800
2022-12-31 $243,035,510 2,830,932
2022-09-30 $137,380,173 2,226,944
2022-09-30 $22,819,131 369,900
2022-09-30 $68,426,548 1,109,200
2022-06-30 $16,126,229 260,900
2022-06-30 $175,607,213 2,841,081

Report a Problem

Category
Description
Email (optional, for follow-up)